RIVA RIVAROXABAN TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

RIVAROXABAN

Inapatikana kutoka:

LABORATOIRE RIVA INC.

ATC kanuni:

B01AF01

INN (Jina la Kimataifa):

RIVAROXABAN

Kipimo:

2.5MG

Dawa fomu:

TABLET

Tungo:

RIVAROXABAN 2.5MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0152487004; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2023-11-01

Tabia za bidhaa

_Page 1 of 111_
_RIVA RIVAROXABAN (rivaroxaban)_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RIVA RIVAROXABAN
Rivaroxaban Tablets
Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, Oral
House standard
Anticoagulant
(ATC Classification: B01AF01)
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control Number: 276851
Date of Initial Authorization:
AUG
25, 2023
_RIVA RIVAROXABAN (rivaroxaban) _
_ _
_Page 2 of 111_
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
..............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
......................................................... 7
4.4
Administration
........................................................................................................
11
4.5
Missed Dose
..............................................................................